文献速递神经肌肉病

神经丝轻链作为遗传性转甲状腺素蛋白淀粉样变性的生物标志物

Neurofilament Light Chain as a Biomarker of Hereditary Transthyretin-Mediated Amyloidosis.
PubMed 文献 · Neurology · 2020-10-21

本研究通过观察性病例对照设计,在APOLLO三期研究中比较了接受安慰剂或patisiran治疗的遗传性转甲状腺素蛋白淀粉样变性多神经病患者与健康对照的血浆蛋白质组。结果显示patisiran显著改变66种蛋白质水平,其中神经丝轻链(NfL)变化最显著(p < 10-20),且NfL水平与神经病变改善相关。结论提示NfL可能作为神经损伤和多神经病的生物标志物,有助于早期诊断和监测疾病进展。

要点

  • patisiran治疗显著降低ATTRv淀粉样变性患者NfL水平,安慰剂组则升高。
  • 健康对照NfL水平为16.3 pg/mL,显著低于患者的69.4 pg/mL。
  • 18个月时NfL下降与mNIS+7评分改善显著相关(R=0.43)。

核心结论

  • NfL可能作为ATTRv淀粉样变性神经损伤和多神经病的生物标志物,有助于早期诊断和监测疾病进展。

研究设计与样本

  • 观察性病例对照研究,比较接受安慰剂或patisiran治疗的ATTRv淀粉样变性多神经病患者与健康对照的血浆蛋白质组。
  • 测量超过1000种蛋白质,在0、9、18个月通过线性混合模型分析patisiran对每种蛋白质时间曲线的影响。
  • NfL进一步用正交定量方法评估。

主要发现

  • patisiran与安慰剂相比,66种蛋白质水平显著改变,其中NfL变化最显著(p < 10-20)。
  • 健康对照NfL水平为16.3 pg/mL,患者为69.4 pg/mL,效应值为-53.1 pg/mL(95%CI -60.5至-45.9)。
  • 18个月时,安慰剂组NfL从基线63.2 pg/mL升至99.5 pg/mL(效应值36.3 pg/mL,95%CI 16.5-56.1),patisiran组从72.1 pg/mL降至48.8 pg/mL(效应值-23.3 pg/mL,95%CI -33.4至-13.1)。
  • 18个月时,patisiran治疗后mNIS+7评分改善与NfL降低显著相关(R=0.43,95%CI 0.29-0.55)。

关键数值与推荐

  • 健康对照NfL水平为16.3 pg/mL,ATTRv淀粉样变性多神经病患者为69.4 pg/mL。
  • 18个月时安慰剂组NfL为99.5 pg/mL(基线63.2 pg/mL),patisiran组为48.8 pg/mL(基线72.1 pg/mL)。
  • mNIS+7评分改善与NfL降低的相关系数R=0.43(95%CI 0.29-0.55)。

临床怎么用

  • NfL可能用于ATTRv淀粉样变性多神经病的早期诊断。
  • NfL可用于监测patisiran治疗下的疾病进展。

局限性

  • 本研究为观察性病例对照设计,证据等级为Class III。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To identify changes in the proteome associated with onset and progression of hereditary transthyretin-mediated (hATTR) amyloidosis, also known as ATTRv amyloidosis, we performed an observational, case-controlled study that compared proteomes of patients with ATTRv amyloidosis and healthy controls. METHODS: Plasma levels of >1,000 proteins were measured in patients with ATTRv amyloidosis with polyneuropathy who received either placebo or patisiran in a Phase 3 study of patisiran (APOLLO), and in healthy controls. The effect of patisiran on the time profile of each protein was determined by linear mixed model at 0, 9, and 18 months. Neurofilament light chain (NfL) was further assessed with an orthogonal quantitative approach. RESULTS: Levels of 66 proteins were significantly changed with patisiran vs placebo, with NfL change most significant (p < 10-20). Analysis of changes in protein levels demonstrated that the proteome of patients treated with patisiran trended toward that of healthy controls at 18 months. Healthy controls' NfL levels were 4-fold lower than in patients with ATTRv amyloidosis with polyneuropathy (16.3 pg/mL vs 69.4 pg/mL, effect -53.1 pg/mL [95% confidence interval -60.5 to -45.9]). NfL levels at 18 months increased with placebo (99.5 pg/mL vs 63.2 pg/mL, effect 36.3 pg/mL [16.5-56.1]) and decreased with patisiran treatment (48.8 pg/mL vs 72.1 pg/mL, effect -23.3 pg/mL [-33.4 to -13.1]) from baseline. At 18 months, improvement in modified Neuropathy Impairment Score +7 score after patisiran treatment significantly correlated with reduced NfL (R = 0.43 [0.29-0.55]). CONCLUSIONS: Findings suggest that NfL may serve as a biomarker of nerve damage and polyneuropathy in ATTRv amyloidosis, enable earlier diagnosis of patients with ATTRv amyloidosis, and facilitate monitoring of disease progression. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that NfL levels may enable earlier diagnosis of polyneuropathy in patients with ATTRv amyloidosis and facilitate monitoring of disease progression.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Ticau S, Sridharan GV, Tsour S, et al. Neurofilament Light Chain as a Biomarker of Hereditary Transthyretin-Mediated Amyloidosis. Neurology. 2020. PMID: 33087494. doi:10.1212/WNL.0000000000011090

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。